ABSTRACT
<b>Background and Objective:</b> Vaname shrimp (<i>Litopenaeus vannamei</i>) is one of the main economic commodities in aquaculture in the world. Biofloc is a cultivation technology that effectively improves the growth and health status of vaname shrimp. This research aimed to analyze the use of bagasse as a carbon source in the biofloc system for white shrimp cultivation. <b>Materials and Methods:</b> The shrimp used were 18 g/individual shrimp obtained from the Bone Marine and Fisheries Polytechnic Pond. Sugarcane bagasse processed from sugar factory waste was dried in an oven at 60°C and ground using a flouring machine. The research treatments included biofloc application where sugarcane bagasse played a role as a carbon source (L), biofloc application where wheat flour's role was as a carbon source (T) and control or no biofloc application (K). <b>Results:</b> This research showed that sugarcane bagasse could be used as a carbon source for white shrimp biofloc cultivation where the growth value tended to be the same as wheat flour. Total hemolytic count (THC) and shrimp survival in sugarcane bagasse biofloc were as good as wheat flour biofloc. Sugarcane bagasse biofloc had the same ability as wheat flour biofloc in reducing ammonia levels in the rearing media. Sugarcane bagasse biofloc had the same ability as wheat flour biofloc in reducing ammonia levels in the rearing media. The application of bagasse had no effect on temperature, pH, dissolved oxygen and salinity of the rearing media because this treatment was in the optimal range for the growth of vaname shrimp. <b>Conclusion:</b> Sugarcane bagasse has the potential to be a carbon source in biofloc systems because it could improve growth, health status, survival and water quality.
Subject(s)
Penaeidae , Saccharum , Animals , Cellulose , Carbon , Ammonia , Flour , Triticum , AquacultureABSTRACT
The study was conducted in three locations: Yogyakarta, Palembang, and Jambi. A total of 355 psychology students from three different universities were recruited using purposive sampling. Among the participants, there were 313 females (88.03%) and 42 males (11.83%). The participants completed several questionnaires in the Indonesian version, including the nomophobia NMP-Q scale (Yildirim & Correia, 2015), the R-UCLA Loneliness Scale (Russell et al., 1980), the self-control scale (Tangney, Baumeister & Boone, 2004), the Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004), and the Spiritual Meaningfulness scale developed based on the theory of Pargament (2007). Before commencing the analysis, the research team ensured the accuracy and reliability of the collected data sets. Participants who did not fully complete the questionnaire were removed from the sample. Ethical clearance for this study was obtained from the research ethics committee, and the researchers obtained permission from the respective university administrations for data collection. Prior to participation, all individuals agreed to take part in the study, provided voluntary informed consent, and were assured of the confidentiality and anonymity of their responses.
ABSTRACT
BACKGROUND: Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer (PCa). However, PCa recurrence and progression rates during ADT are high. Until now, there has been no evidence regarding when progression begins. This study evaluated the gene expression of intraprostatic androgen receptor (AR) and steroidogenic enzymes in the early stages of ADT. METHODS: Prostate tissue samples were taken from PCa patients with urinary retention who received ADT (ADT-PCa; n = 10) and were further subgrouped into ADT ≤12 months (n = 4) and ADT > 12 months (n = 6). The ADT-PCa tissues were then compared with BPH (n = 12) and primary (no treatment) PCa tissues (n = 16). mRNA for gene expression analysis of AR and steroidogenic enzymes was extracted from formalin-fixed paraffin embedded (FFPE) tissues and analyzed by real-time PCR. Protein expression was evaluated by immunohistochemistry with specific antibodies. RESULTS: AR gene expression was higher in the ADT-PCa group than in the BPH or primary PCa group. Both the ADT ≤12 and > 12 months subgroups had significantly higher relative gene expression levels of AR (p < 0.01 and 0.03, respectively) than the primary PCa group. In the ADT-PCa group, AR protein expression showed an increasing trend in the ADT ≤12 months subgroup and was significantly elevated in the ADT > 12 months subgroup compared with the PCa group (100%; p < 0.01). Half (50%) of the patients in the ADT ≤12 months subgroup were found to have upregulation of AR, and one showed upregulation beginning at 3 months of ADT. A trend toward elevated relative gene expression of SRD5A3 was also apparent in the ADT groups. CONCLUSION: AR and steroidogenic enzymes are upregulated in ADT-PCa patients as early as 3 months, without PSA elevation. Steroidogenic enzymes, particularly SRD5A3, were also upregulated before PSA rose.